Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on breast cancer biomarkers from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Bachelot comments on biomarker findings from breast cancer studies.

He first talks about exploratory results from the PADA-1 study looking at prognostic impact of ESR1 mutations in patients with ER-positive, HER2-negative metastatic breast cancer treated with first-line palbociclib combined with an aromatase inhibitor. Secondly he discusses the results of ctDNA investigation from the pooled analysis of three phase III MONALEESA trials, assessing ribociclib in metastatic breast cancer patients for informing future treatment strategy.


  • 1010: Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial - François-Clément Bidard
  • 1009: Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials - Fabrice André 

This video was supported with an educational grant from Daiichi Sankyo and Novartis. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.